Autophagy, Metabolism, and Cancer

Clinical Cancer Research

Volumn 21, Issue 22, 2015, Pages 5037-5046

  White, Eileen ^a,b   Mehnert, Janice M ^a,c   Chan, Chang S ^a,c  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; BRCA1 PROTEIN; HYDROXYCHLOROQUINE;

AUTOPHAGOSOME; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DRUG EFFECT; ENERGY METABOLISM; GENE DOSAGE; GENE LOSS; GENE MUTATION; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR PROMOTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; MOUSE; NEOPLASMS; PATHOLOGY;

ANIMALS; AUTOPHAGY; CARCINOGENESIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICE; MITOCHONDRIA; NEOPLASMS; OXIDATIVE STRESS;

EID: 84954190444     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0490     Document Type: Review

References (87)

1. Mizushima N, Yoshimori T, Ohsumi Y. The role of atg proteins in autophagosome formation. Annu Rev Cell Dev Biol 2011;27:107-32.
2. Rabinowitz JD, White E. Autophagy and metabolism. Science 2010;330: 1344-8.
3. Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, et al. Selective vps34 inhibitor blocks autophagy and uncovers a role for ncoa4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol 2014; 16:1069-79.
4. Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies ncoa4 as the cargo receptormediating ferritinophagy. Nature 2014;509:105-9.
5. White E. The role for autophagy in cancer. J Clin Invest 2015;125:42-6.
6. Mathew R, Khor S, Hackett SR, Rabinowitz JD, Perlman DH, White E. Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity. Mol Cell 2014;55: 916-30.
7. Mizushima N, Komatsu M. Autophagy: Renovation of cells and tissues. Cell 2011;147:728-41.
8. Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S, et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov 2014;4:914-27.
9. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, et al. The role of autophagy during the early neonatal starvation period. Nature 2004;432:1032-6.
10. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999;59:59-65.
11. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999;402:672-6.
12. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013;13:722-37.
13. Karantza-Wadsworth V, Patel S, Kravchuk O, ChenG,Mathew R, Jin S, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007;21:1621-35.
14. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009;137:1062-75.
15. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007;21:1367-81.
16. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012;12:401-10.
17. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011;25:795-800.
18. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, et al. P53 status determines the role of autophagy in pancreatic tumour development. Nature 2013;504:296-300.
19. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 2014;4:905-13.
20. KomatsuM,Waguri S, Koike M, Sou YS, Ueno T,Hara T, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagydeficient mice. Cell 2007;131:1149-63.
21. Strohecker AM, White E. Targeting mitochondrial metabolism by inhibiting autophagy in braf-driven cancers. Cancer Discov 2014;4:766-72.
22. Cicchini M, Chakrabarti R, Kongara S, Price S, Nahar R, Lozy F, et al. Autophagy regulator becn1 suppresses mammary tumorigenesis driven by wnt1 activation and following parity. Autophagy 2014;10:2036-52.
23. Rohatgi RA, Janusis J, Leonard D, Bellve KD, Fogarty KE, Baehrecke EH, et al. Beclin 1 regulates growth factor receptor signaling in breast cancer. Oncogene 2015;34:5352-62.
24. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013;368:651-62.
25. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003;112:1809-20.
26. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 2003;100:15077-82.
27. Laddha SV, Ganesan S, Chan CS, White E. Mutational landscape of the essential autophagy gene becn1 in human cancers. Mol Cancer Res 2014;12:485-90.
28. Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, et al. Decreased mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis. EBioMedicine 2015;2: 255-63.
29. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, et al. Parkin, a gene implicated in autosomal recessive juvenile Parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 2003;100:5956-61.
30. Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E, Raheja R, et al. Pancancer genetic analysis identifies park2 as amaster regulator of g1/s cyclins. Nat Genet 2014;46:588-94.
31. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, et al. The signaling adaptor p62 is an important nf-kappab mediator in tumorigenesis. Cancer Cell 2008;13:343-54.
32. Wei H, Wang C, Croce CM, Guan JL. P62/sqstm1 synergizes with autophagy for tumor growth in vivo Genes Dev 2014;28:1204-16.
33. Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, et al. Sqstm1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell 2013;24:738-50.
34. Moscat J, Diaz-Meco MT. P62: A versatile multitasker takes on cancer. Trends Biochem Sci 2012;37:230-6.
35. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006;10:51-64.
36. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011;25:460-70.
37. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, et al. Autophagy suppresses progression of k-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013;27: 1447-61.
38. Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate lc3b expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res 2012;18:370-9.
39. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, et al. Autophagy facilitates glycolysis during ras-mediated oncogenic transformation. Mol Biol Cell 2011;22:165-78.
40. Ma XH, Piao S, Wang D, McAfee QW, Nathanson KL, Lum JJ, et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 2011; 17:3478-89.
41. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011;25: 717-29.
42. Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 2015;524:361-5.
43. Ferguson SM. Beyond indigestion: Emerging roles for lysosome-based signaling in human disease. Curr Opin Cell Biol 2015;35:59-68.
44. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11:24-37.
45. Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014;5:3056.
46. Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell 2013;155:1216-9.
47. Guo JY, White E. Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of kras(g12d)-driven lung tumors. Autophagy 2013;9:1636-8.
48. Strohecker AM, White E. Autophagy promotes brafv600e-driven lung tumorigenesis by preserving mitochondrial metabolism. Autophagy 2014;10:384-5.
49. Amaravadi R, Debnath J. Mouse models address key concerns regarding autophagy inhibition in cancer therapy. Cancer Discov 2014;4:873-5.
50. Wei H, Wei S, Gan B, Peng X, Zou W, Guan JL. Suppression of autophagy by fip200 deletion inhibits mammary tumorigenesis. Genes Dev 2011; 25:1510-27.
51. Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 overcomes senescence and promotes growth of brafv600e-driven melanoma. Cancer Discov 2015; 5:410-23.
52. Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S, et al. Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of palb2-associated hereditary breast cancer. Cancer Discov 2013;3:894-907.
53. Xie X, White EP, Mehnert JM. Coordinate autophagy and mtor pathway inhibition enhances cell death in melanoma. PLoS ONE 2013;8: E55096.
54. Sheen JH, Zoncu R, Kim D, SabatiniDM. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of humanmelanoma cells in vitro and in vivo. Cancer Cell 2011;19:613-28.
55. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, et al. Targeting er stress-induced autophagy overcomes braf inhibitor resistance in melanoma. J Clin Invest 2014;124:1406-17.
56. Lock R, Kenific CM, Leidal AM, Salas E, Debnath J. Autophagy-dependent production of secreted factors facilitates oncogenic ras-driven invasion. Cancer Discov 2014;4:466-79.
57. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, et al. Impairment of starvation-induced and constitutive autophagy in atg7-deficient mice. J Cell Biol 2005;169:425-34.
58. Cheong H, Wu J, Gonzales LK, Guttentag SH, Thompson CB, Lindsten T. Analysis of a lung defect in autophagy-deficient mouse strains. Autophagy 2014;10:45-56.
59. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004;15:1101-11.
60. Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in cancer. Oncogene 2015 Apr 20. [Epub ahead of print].
61. Levy JM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, et al. Autophagy inhibition improves chemosensitivity in braf(v600e) brain tumors. Cancer Discov 2014;4:773-80.
62. Mahalingam D, Mita M, Sarantopoulos J,WoodL,Amaravadi RK, Davis LE, et al. Combined autophagy and hdac inhibition: A phase i safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the hdac inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014;10:1403-14.
63. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, et al. Combined mtor and autophagy inhibition: Phase i trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014;10:1391-402.
64. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, et al. Phase i trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors andmelanoma. Autophagy 2014;10: 1369-79.
65. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014;10:1359-68.
66. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, et al. Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014;10:1380-90.
67. Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, et al. Inhibition of autophagy enhances the effects of the akt inhibitor mk-2206 when combined with paclitaxel and carboplatin in braf wild-type melanoma. Pigment Cell Melanoma Res 2014;27:465-78.
68. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, et al. Autophagy inhibitor lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A 2012;109:8253-8.
69. White E. Exploiting the bad eating habits of ras-driven cancers. Genes Dev 2013;27:2065-71.
70. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in ras-transformed cells. Nature 2013;497:633-7.
71. Pasquier B, El-AhmadY, Filoche-Romme B, Dureuil C, Fassy F, Abecassis PY, et al. Discovery of (2s)-8-[(3r)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2h-pyrimido[1,2-a]pyrimidin-6-one: A novel potent and selective inhibitor of vps34 for the treatment of solid tumors. J Med Chem 2015;58:376-400.
72. Ronan B, FlamandO, Vescovi L, Dureuil C, Durand L, Fassy F, et al. Ahighly potent and selective vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol 2014;10:1013-9.
73. Petherick KJ, Conway OJ, Mpamhanga C, Osborne SA, Kamal A, Saxty B, et al. Pharmacological inhibition of ulk1 kinase blocks mammalian target of rapamycin (mtor)-dependent autophagy. J Biol Chem 2015;290: 11376-83.
74. Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, et al. Small molecule inhibition of the autophagy kinase ulk1 and identification of ulk1 substrates. Mol Cell 2015;59:285-97.
75. Tran E, Chow A, Goda T, Wong A, Blakely K, Rocha M, et al. Context-dependent role of atg4b as target for autophagy inhibition in prostate cancer therapy. Biochem Biophys Res Commun 2013; 441:726-31.
76. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ros generation are essential for kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010;107: 8788-93.
77. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial. DNA Cell Metab 2015;21:81-94.
78. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N,MarchesiniM, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014;514:628-32.
79. Gasparre G, Romeo G, Rugolo M, Porcelli AM. Learning from oncocytic tumors: Why choose inefficient mitochondria? Biochim Biophys Acta 2011;1807:633-42.
80. Hu J, Locasale JW, Bielas JH, O'Sullivan J, Sheahan K, Cantley LC, et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol 2013;31:522-9.
81. Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, et al. Shmt2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature 2015;520:363-7.
82. Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013;123:3693-700.
83. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014;508:108-12.
84. Fulda S. Promises and challenges of smac mimetics as cancer therapeutics. Clin Cancer Res 2015;21:5030-6.
85. Gibson CJ, DavidsMS. BCL-2 antagonism to target the intrinsic mitochondrial pathway of apoptosis. Clin Cancer Res 2015;21:5021-9.
86. Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer Metab 2014;2:10.
87. Mandelbaum J, Rollins N, Shah P, Bowman D, Lee JY, Tayber O, et al. Identification of a lung cancer cell line deficient in atg7-dependent autophagy. Autophagy 2015 Jun 19. [Epub ahead of print].